Sermorelin was previously FDA-approved for diagnostic use (Geref) but has been discontinued by its manufacturer
A relative decline in the efficiency of this potential compensatory mechanism, resulting in a less robust Gln-Glu cycle, may contribute to the manifestation of sensory sensitivity-related symptoms
A systematic review published in Current Treatment Options in Psychiatry analyzed 81 human and animal studies and concluded that GLP-1 receptor agonists showed potential benefits for depressive symptoms, anxiety, cognitive function, binge eating, and alcohol or substance use disorders (3 Trusted Source The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review Go to source)
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
Our team reviews current criteria at the time of your consultation
Pregnant or breastfeeding women there is currently insufficient safety data to support use during pregnancy or lactation